Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys, Astellas Extend Antibody Library License

NEW YORK (GenomeWeb News) – The German antibody developer Morphosys has extended an agreement with Astellas Pharma that allows the Japanese pharmaceutical company to use the HuCAL Gold antibody library for therapeutics development for four more years.
 
The companies extended an agreement they signed in March 2007 that gives Astellas access to the antibody library at its Tsukuba, Japan, facility through 2012, and they renewed an option for commercialization and development of therapeutic antibodies.
 
Under the agreement, MorphySys will receive annual user fees for the HuCAL platform and may receive exclusive license fees, milestones, and royalty payments from any therapeutics Astellas markets that were derived from MorphySys’ technology.
 

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.